Does lisdexamfetamine exacerbate or alleviate symptoms in patients with alpha-1 antitrypsin deficiency?

Zenodo (CERN European Organization for Nuclear Research) 2026 Open access

Read full text
Authors: Tripdatabase
DOI: 10.5281/zenodo.18222911
Cited by: 0

Abstract

There is no available evidence that directly addresses the impact of lisdexamfetamine on symptoms in patients with alpha-1 antitrypsin deficiency.

Fields of Study & Subjects

Chronic Obstructive Pulmonary Disease (COPD) Research Pharmacogenetics and Drug Metabolism Parkinson's Disease Mechanisms and Treatments

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
12 January 2026